Accéder au contenu
Merck

Functional Genomics Identifies Metabolic Vulnerabilities in Pancreatic Cancer.

Cell metabolism (2020-11-06)
Douglas E Biancur, Kevin S Kapner, Keisuke Yamamoto, Robert S Banh, Jasper E Neggers, Albert S W Sohn, Warren Wu, Robert T Manguso, Adam Brown, David E Root, Andrew J Aguirre, Alec C Kimmelman
RÉSUMÉ

Pancreatic ductal adenocarcinoma (PDA) is a deadly cancer characterized by complex metabolic adaptations that promote survival in a severely hypoxic and nutrient-limited tumor microenvironment (TME). Modeling microenvironmental influences in cell culture has been challenging, and technical limitations have hampered the comprehensive study of tumor-specific metabolism in vivo. To systematically interrogate metabolic vulnerabilities in PDA, we employed parallel CRISPR-Cas9 screens using in vivo and in vitro systems. This work revealed striking overlap of in vivo metabolic dependencies with those in vitro. Moreover, we identified that intercellular nutrient sharing can mask dependencies in pooled screens, highlighting a limitation of this approach to study tumor metabolism. Furthermore, metabolic dependencies were similar between 2D and 3D culture, although 3D culture may better model vulnerabilities that influence certain oncogenic signaling pathways. Lastly, our work demonstrates the power of genetic screening approaches to define in vivo metabolic dependencies and pathways that may have therapeutic utility.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps monoclonal anti-β-actine antibody produced in mouse, clone AC-74, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Conalbumin from chicken egg white, Substantially iron-free
Sigma-Aldrich
TAK-475, ≥98% (HPLC)